Skip to main content
Caplight Logo









Nunaps

Nunaps

Private
SeoulHealthcare & Life Scienceshttps://www.nunaps.com/

Last Round

Series B

Jan 1, 2025

Total Funding Raised

$13.47M

Company Overview

Nunaps is a digital therapeutics company that develops software-based medical devices and platforms to treat and manage neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical AI, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

digital therapeuticsDTxsoftware as a medical deviceSaMDvirtual reality therapyneuro-rehabilitationvisual field defectsmedical AIneuroplasticitystroke recoverydigital healthclinical-stage softwarehealthtechvisual perceptual learningneurological disorders

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nunaps Comparables

Compare Nunaps with similar companies based on industry and business-model similarity.

Nunaps comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Emocog
78%
HAII
76%
Incline Equity Partners
74%

Nunaps Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 1, 2025
Series AJan 5, 2020
SeedDec 1, 2017

Nunaps Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Grew 200% QoQ, from 2 to 6 employees.

  • Mar 14, 2026

    Grew 500% QoQ from 1 to 6 employees.

Recent news

Latest coverage and updates

  • receives_financingAug 18, 2026

    Nunaps Inc. receives financing of $15.5M in Series B.

  • is_developingAug 18, 2026

    Nunaps Inc. is developing Lexure: Digital therapeutic for patients with language disorders.

Nunaps Filings

Explore SEC and related filing metadata, where available.

Nunaps filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nunaps's valuation, stock price, and market status.

Is Nunaps a public or private company?

Nunaps is a private company.

What is the current stock price of Nunaps?

Nunaps is a private company with no public stock price. No recent secondary market data is available.

How much is Nunaps worth (valuation)?

Valuation information for Nunaps is not publicly available.

Can I buy Nunaps stock?

Nunaps shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nunaps's last funding round?

Nunaps's most recent funding round was Series B on January 1, 2025.

Who are the main investors in Nunaps?

Key investors in Nunaps include Hanwha Investment & Securities, K2 Investment Partners, Smilegate Investment, Prodigy Investment, Company K Partners.

Will Nunaps IPO soon?

No public IPO plans have been announced for Nunaps.

How can I track Nunaps secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nunaps's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Employee Range8
Year Founded2017
Last FundingJan 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?